EUVIMEDObjevte EUVIMED
Crossref

Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide

Sarah R Barenbaum, Ariel Gonzalez, Zoe Verzani, Alice S Zhao, Alpana P Shukla

Obesity · 2026-06 · 34 (S1) · 97-101

DOI: 10.1002/oby.70179 ↗

At a glance

Journal article in Obesity, 2026-06. Written by Sarah R Barenbaum and 4 co-authors. Institution: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, Ne…. Major MEDLINE topics: Tirzepatide, Weight Loss, Obesity, Glucagon-Like Peptides. Cited 2 times so far (Crossref); 10 references. Funded by: Clinical and Translational Science Center, Weill Cornell Medical College, Clinical and Translational Science Center, Weill Cornell Medicine.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

This study compared weight‐loss outcomes in patients prescribed tirzepatide by weight‐loss status and assessed results among patients transitioning from semaglutide.

Methods

This retrospective cohort study analyzed 6‐month weight‐loss outcomes in adults treated with tirzepatide between May 2022 and January 2023. Patients were classified as weight‐reduced if they had lost ≥ 10% total body weight (TBW) before starting tirzepatide. Among those who switched from therapeutic semaglutide (≥ 1.7 mg weekly for ≥ 1 month), reasons for switching were categorized as non‐response (< 5% weight loss after ≥ 3 months), plateau (≥ 5% loss followed by weight stabilization), or other.

Results

Of 941 charts, 293 (31.1%) met inclusion criteria (65% female; mean age 52 years; mean BMI 36.15 kg/m 2 ). Weight‐reduced patients ( n = 133) lost 7.2% TBW versus 10.3% in non‐weight‐reduced patients ( n = 160; p < 0.001). When analyses were stratified by type 2 diabetes (T2D) status, this difference remained significant among patients without T2D. Sixty‐one patients switched from semaglutide due to non‐response or plateau and lost 5.3% TBW. Those switching at a plateau ( n = 28) lost 8.1% versus 2.9% for non‐responders ( n = 33; p < 0.001).

Conclusions

Tirzepatide produced meaningful weight loss across groups but outcomes varied based on weight‐reduction status, T2D status, and prior response to semaglutide.

Subjects

MeSH terms (MEDLINE)

TirzepatideWeight LossObesityGlucagon-Like PeptidesAnti-Obesity AgentsHumansFemaleMiddle AgedSemaglutideRetrospective StudiesMaleTreatment OutcomeAdultAgedBody Mass IndexDiabetes Mellitus, Type 2

Substances

TirzepatideSemaglutideGlucagon-Like PeptidesAnti-Obesity Agents

Authors and institutions

  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA.
  • Weill Cornell Medical College, New York, New York, USA.
  • Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.
  • Department of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Funding

  • Clinical and Translational Science Center, Weill Cornell Medical College
  • Clinical and Translational Science Center, Weill Cornell Medicine

Cite

APA

Barenbaum, S. R., Gonzalez, A., Verzani, Z., Zhao, A. S., & Shukla, A. P. (2026). Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide. Obesity. https://doi.org/10.1002/oby.70179

Vancouver

Barenbaum SR, Gonzalez A, Verzani Z, Zhao AS, Shukla AP. Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide. Obesity. 2026. doi:10.1002/oby.70179

BibTeX
@article{Barenbaum2026,
  author = {Barenbaum, Sarah R and Gonzalez, Ariel and Verzani, Zoe and Zhao, Alice S and Shukla, Alpana P},
  title = {Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70179}
}
Start for free →